Role of Topical Nepafenac in Prevention and Treatment of Macular Edema After Vitreoretinal Surgery

Naithani, Prashant; Puranik, Shraddha; Vashisht, Naginder; Khanduja, Sumeet; Kumar, Sanjeev; Garg, Satpal

doi:10.1097/iae.0b013e31821e2057

Cited by 17 publications

(27 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After thirty days there was no difference noted in relation to the above-mentioned parameters of inflammation in both groups. In another study by Naithani et al .,[15] patients given nepafenac had significantly less intraocular inflammation on day one, postoperatively, as compared to those who received placebo drops. However, in this study the drops were started three days preoperatively in both the groups and were given in addition to topical prednisolone.…”

Section: Discussionmentioning

confidence: 99%

“…However, there was no statistically significant difference in the pain scores between both the groups. Naithani et al .,[15] found that individuals put on nepafenac were statistically significantly less likely to have postoperative eye pain than those in the placebo group.…”

Section: Discussionmentioning

confidence: 99%

“…[13] Topical ketorolac (0.4%)[14] and topical nepafenac (0.1%)[15] are found to be safe and effective in reducing pain and inflammation in patients undergoing vitreoretinal surgery. Naithani et al .,[15] have conducted an investigator-masked, randomized study to evaluate the effect of topical nepafenac on intraocular inflammation, pain, and postoperative macular edema, in patients undergoing vitreoretinal surgery. They have compared the effect of nepafenac to a placebo group as an adjunct to the regular prednisolone eye drops.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Topical nepafenac 0.1% alone versus prednisolone acetate 1% as postoperative anti-inflammatory agents in small gauge vitrectomy

Nagpal¹,

Lambat²,

Mehrotra³

et al. 2014

Indian J Ophthalmol

View full text Add to dashboard Cite

Aim:To compare the efficacy of postoperative topical nepafenac (0.1%) with prednisolone acetate (1%) as anti-inflammatory agents in eyes undergoing Transscleral Sutureless Vitrectomy (TSV).Settings and Design:Prospective, double-blind, randomized, single center clinical study.Materials and Methods:Eighty eyes of 76 subjects, who underwent small gauge vitrectomy, were included in the study. The subjects who fulfilled the inclusion criteria were randomized to either topical nepafenac only (Group 1) or prednisolone acetate only (Group 2), to be used as postoperative anti-inflammatory agents. The subjects were reviewed on days 1, 30, and 90. Ocular and adnexal inflammation was appropriately graded using the standardized classification. Grading of ocular pain was done on the Visual Analog Scale (VAS).Statistical Analysis:The Wilcoxon rank-sum test, using two-sided analysis, was used.Results:During the follow-up, both Group 1 and Group 2 did not have a significant difference related to the grade of the anterior chamber inflammation (P > 0.05) or adnexal inflammation (P > 0.05). Pain perception was less in the subjects in Group 1 as compared to subjects in Group 2, but was not statistically significant (P > 0.05).Conclusion:Postoperative topical nepafenac was non-inferior to prednisolone acetate in reducing postoperative ocular inflammation in eyes undergoing TSV.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Topical nepafenac 0.1% alone versus prednisolone acetate 1% as postoperative anti-inflammatory agents in small gauge vitrectomy

Nagpal¹,

Lambat²,

Mehrotra³

et al. 2014

Indian J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…2011), pain and inflammation after vitreoretinal surgery (Naithani et al. 2012), acute central chorioretinopathy (Alkin et al. 2013), postoperative inflammation after small‐gauge vitrectomy (Nagpal et al.…”

Section: Discussionmentioning

confidence: 99%

Ophthalmic nepafenac use in the Netherlands and Denmark

Margulis¹,

Houben

Hallas

et al. 2017

Acta Ophthalmologica

View full text Add to dashboard Cite

PurposeTo describe nepafenac use in the Netherlands and Denmark with reference to its approved indications. For context, we also describe the use of ketorolac and diclofenac.MethodsWe identified users in the PHARMO Database Network (the Netherlands, 2008–2013) and the Danish national health registers (Denmark, 1994–2014). We described prevalence of cataract surgery and duration of use in patients with cataract surgery with and without diabetes.ResultsIn the Netherlands, 9530 nepafenac users (mean age, 71 years; 60% women) contributed 12 691 therapy episodes, of which 21% had a recently recorded cataract surgery. Of 2266 episodes in adult non‐diabetic patients with cataract surgery, 60% had one bottle dispensed (treatment duration ≤21 days). Of 441 episodes in adult diabetic patients with cataract surgery, 90% had up to two bottles dispensed (≤60 days).Denmark had 60 403 nepafenac users (mean age, 72 years; 58% women) and 73 648 episodes (41% had recorded cataract surgery). Of 26 649 nepafenac episodes in adult non‐diabetic patients with cataract surgery, 92% had one bottle dispensed. Of 3801 episodes in adult diabetic patients with cataract surgery, 99.8% had up to two bottles dispensed.Use patterns of nepafenac, ketorolac and diclofenac were roughly similar in the Netherlands, but not in Denmark.ConclusionLess than half of therapy episodes were related to cataract surgery; around 90% of episodes with surgery were within the approved duration. Underrecording of ophthalmic conditions and procedures was a challenge in this study.

show abstract

“…A prospective, randomized, placebo-controlled trial reported that topical ketorolac 0.4% reduced both retinal thickness (9%) and total macular volume (6%) but neither outcome reached statistical significance [29]. Schoenberger et al reported that topical nepafenac more rapidly reduced macular volume in patients undergoing epiretinal membrane surgery, but this effect was not observed by another study using nepafenac [30, 31]. …”

Section: Postoperative Cystoid Macular Edemamentioning

confidence: 99%

Nonsteroidal Anti-Inflammatory Drugs for Retinal Disease

Schoenberger

Kim

2013

International Journal of Inflammation

View full text Add to dashboard Cite

Nonsteroidal anti-inflammatory drugs (NSAIDs) are used extensively in ophthalmology for pain and photophobia after photorefractive surgery and to reduce miosis, inflammation, and cystoid macular edema following cataract surgery. In recent years, the US Food and Drug Administration has approved new topical NSAIDs and previously approved NSAIDs have been reformulated. These changes may allow for greater drug penetration into the retina and thereby offer additional therapeutic advantages. For example, therapeutic effects on diabetic retinopathy and age-related macular degeneration may now be achievable. We provide an updated review on the scientific rationale and clinical use of NSAIDs for retinal disease.

show abstract

Role of Topical Nepafenac in Prevention and Treatment of Macular Edema After Vitreoretinal Surgery

Cited by 17 publications

References 16 publications

Topical nepafenac 0.1% alone versus prednisolone acetate 1% as postoperative anti-inflammatory agents in small gauge vitrectomy

Topical nepafenac 0.1% alone versus prednisolone acetate 1% as postoperative anti-inflammatory agents in small gauge vitrectomy

Ophthalmic nepafenac use in the Netherlands and Denmark

Nonsteroidal Anti-Inflammatory Drugs for Retinal Disease

Contact Info

Product

Resources

About